既往蛛网膜下腔出血患者复发及新增动脉瘤的择期治疗:单中心并发症与临床结局分析
该单中心回顾性研究纳入2010至2018年接受择期手术或血管内治疗的337例患者(既往SAH组67例,无SAH组270例),比较两组并发症率与6个月功能结局。既往SAH组与无SAH组 procedure相关并发症率分别为13.5%和13.3%(P=1.0),6个月mRS增加分别为6.7%和7.6%(P=0.5),mRS≤2分分别为96.6%和97.3%(P=1.0)。作者认为既往SAH患者复发或新增动脉瘤的择期治疗并发症率和致残率可接受。
要点
- 既往SAH患者复发或新增动脉瘤择期治疗并发症率13.5%,与无SAH患者13.3%无显著差异(P=1.0)。
- 6个月mRS增加在SAH组为6.7%,非SAH组为7.6%(P=0.5),无显著差异。
- 6个月良好结局(mRS≤2)SAH组96.6%,非SAH组97.3%(P=1.0),无显著差异。
核心结论
- 既往SAH患者复发或新增动脉瘤的择期治疗可通过手术或血管内方式完成,并发症率和致残率可接受。
研究设计与样本
- 回顾性单中心研究,纳入2010至2018年接受择期手术或血管内治疗的患者337例(无SAH组270例,SAH组67例),共390次择期手术、443个动脉瘤。
主要发现
- 手术相关并发症在既往SAH组为13.5%,无SAH组为13.3%(P=1.0)。
- 6个月随访时,致残(定义为mRS任何增加)在SAH组为6.7%,非SAH组为7.6%(P=0.5)。
- 总体良好结局(mRS评分≤2)在SAH组为96.6%,非SAH组为97.3%(P=1.0)。
- 在既往SAH患者中,选择夹闭或血管内治疗对6个月随访临床结局无显著影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Subarachnoid hemorrhage (SAH) can be associated with a degree of resulting brain damage and subsequent reorganization of the central nervous system. The aim of this study was to evaluate complication rates and clinical outcome in patients with a previous SAH who were treated for a recurrent or an additional, initially unruptured aneurysm. METHODS: A retrospective single-center study was conducted for patients who underwent elective treatment by surgical or endovascular means between 2010 and 2018. We compared patients with a previous SAH and without history of SAH in terms of complication rates and functional outcomes (modified Rankin Scale [mRS]). RESULTS: The study population consisted of 337 patients (non-SAH, 270; SAH, 67) who underwent 390 elective procedures for treatment of 443 aneurysms. Procedure-related complications occurred in 13.5% of patients with a previous SAH and in 13.3% of patients without SAH (P = 1.0). At the 6-month follow-up, the morbidity (defined as any increase on the mRS) was comparable between the SAH group (6.7%) and the non-SAH group (7.6%; P = 0.5). Overall favorable outcome (mRS score ≤2) was achieved by 96.6% in the SAH group and 97.3% in the non-SAH group (P = 1.0). Also, in patients with a previous SAH, the choice of clipping or endovascular treatment did not have a significant impact on clinical outcome at the 6-month follow-up. CONCLUSIONS: Treatment of recurrent or additional aneurysms in patients with a previous SAH can be performed with acceptable complication rates and morbidity by either surgical or endovascular means.
引用
- Goertz L, Brinker G, Hamisch C, et al. Elective Treatment of Additional and Recurrent Aneurysms in Patients with a Previous Subarachnoid Hemorrhage: A Single-Center Analysis of Complications and Clinical Outcome. World Neurosurg. 2019. PMID: 30794974. doi:10.1016/j.wneu.2019.01.279
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。